Orion Oyj
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Liisa Hurme
- Full Time Employees
- 3,943
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Orionintie 1A Espoo UU Finland 02200
- IPO Date
- Dec 9, 2014
- Website
- orionpharma.com
- Similar Companies
- Business
- Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland, develops, manufactures and markets human pharmaceuticals, veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) for global markets, with all manufacturing sites and most R&D units located in Finland. The company's human pharmaceutical portfolio includes proprietary branded products such as Nubeqa for prostate cancer treatment; Entacapone, Stalevo, Comtess and Comtan for Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex and Dexmedetomidine for sedation and intensive care, alongside generic drugs, self-care products including non-prescription medicines and vitamins, and diagnostic tests; its veterinary offerings cover pain management, sedation, joint and mobility support, behavioral balance, gastrointestinal balance, eye and ear care, dental care, skin and fur treatments, and health recovery products for companion animals and livestock; through its subsidiary Fermion, Orion produces APIs for internal use and external contract manufacturing customers worldwide. Orion focuses R&D on core therapeutic areas including oncology, neurological disorders such as Parkinson's and insomnia, pain management, respiratory diseases and inhaled pulmonary medications, serving specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics and laboratories across international markets with primary operations in Europe, North America and other regions. Recent developments include an exclusive commercial license agreement in October 2025 with Abzena for a monoclonal antibody targeting a high unmet-need cancer, strengthening Orion's oncology pipeline; a EUR 180 million milestone payment received in December 2025 related to Nubeqa sales, accompanied by an updated full-year 2025 outlook; the phase 2 study of ODM-105 for insomnia not meeting its primary goal in September 2025; multiple share conversions from A to B shares throughout 2025 including 71,498 shares in November and 49,164 in October; and receipt of the President of Finland's international growth award in November 2025.
Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript
Orion Oyj (ORINF) Q4 2025 Earnings Call Transcript
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Oyj (ORINF) Q3 2025 Earnings Call Transcript
What Makes Orion OYJ (ORINY) a Good Fit for 'Trend Investing'
5 Stocks With Recent Price Strength to Maximize Your Gains
Here is Why Growth Investors Should Buy Orion OYJ (ORINY) Now
Orion OYJ (ORINY) is on the Move, Here's Why the Trend Could be Sustainable
Orion Oyj (ORINF) Q2 2025 Earnings Call Transcript
Looking for a Growth Stock? 3 Reasons Why Orion OYJ (ORINY) is a Solid Choice
Recent Price Trend in Orion OYJ (ORINY) is Your Friend, Here's Why
ORION Holdings Corp. (ORINF) Q1 2025 Earnings Call Transcript
Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why
Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"
Orion Oyj (ORINF) Q4 2023 Earnings Call Transcript